Publicaciones (42) Publicaciones de PABLO MINGUEZ GABIÑA

2024

  1. Implementation of dosimetry for molecular radiotherapy; results from a European survey

    Physica Medica, Vol. 117

  2. Symposium on molecular radiotherapy dosimetry: The first of a series?

    Physica Medica

2023

  1. Activity recovery for differently shaped objects in quantitative SPECT

    Physics in Medicine and Biology, Vol. 68, Núm. 12

  2. An EANM position paper on advancing radiobiology for shaping the future of nuclear medicine

    European Journal of Nuclear Medicine and Molecular Imaging

  3. Correction to: EANM enabling guide: how to improve the accessibility of clinical dosimetry (European Journal of Nuclear Medicine and Molecular Imaging, (2023), 50, 7, (1861-1868), 10.1007/s00259-023-06226-z)

    European Journal of Nuclear Medicine and Molecular Imaging

  4. EANM enabling guide: how to improve the accessibility of clinical dosimetry

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 7, pp. 1861-1868

  5. EANM practice guideline for quantitative SPECT-CT

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 4, pp. 980-995

  6. EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy – Molecular radiotherapy

    Physica Medica, Vol. 116

  7. Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE

    EJNMMI Physics, Vol. 10, Núm. 1

  8. Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry

    European Journal of Nuclear Medicine and Molecular Imaging

2022

  1. Alpha particle microdosimetry calculations using a shallow neural network

    Physics in Medicine and Biology, Vol. 67, Núm. 2

  2. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Núm. 6, pp. 1778-1809

2021

  1. A retrospective study on the potential of 99mTc-HDP imaging before therapy for individualizing treatments with 223Ra-Cl2 for metastatic castration resistant prostate cancer

    Medical Physics, Vol. 48, Núm. 3, pp. 1395-1403

  2. Dependency of the remnant 131I-NaI biokinetics on the administered activity in patients with differentiated thyroid cancer

    Physica Medica, Vol. 88, pp. 45-52

  3. EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres

    EJNMMI Physics, Vol. 8, Núm. 1

  4. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: Toxicity, prostatespecific antigen kinetics, and cancer control

    Journal of Contemporary Brachytherapy, Vol. 13, Núm. 1, pp. 12-17

2020

  1. EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours

    EJNMMI Physics, Vol. 7, Núm. 1

  2. Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies

    European Journal of Nuclear Medicine and Molecular Imaging

  3. Feasibility and limitations of quantitative SPECT for 223Ra

    Physics in Medicine and Biology, Vol. 65, Núm. 8

  4. MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?

    Clinical and Translational Radiation Oncology, Vol. 24, pp. 135-139